Publication date: Jun 23, 2025
Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess the relationship between atopy and survival or reduced BrM cumulative incidence (CI) in melanoma. This retrospective study was conducted in individuals (≥65 years) in linked Surveillance, Epidemiology and End Results and Medicare data. History of atopy diagnosed prior to melanoma was ascertained using ICD-9/ICD-10 codes. Associations between atopy, CI of BrM and overall survival were assessed using cox proportional hazards models to estimate hazard ratios (HR) and p-values. A total of 23,508 cutaneous melanoma cases were identified. Overall, 6. 1% developed BrM, and 38% had history of atopy. Atopy was associated with a 18% decrease in death (p
| Concepts | Keywords |
|---|---|
| Biomarkers | Atopy |
| Epidemiology | Brain |
| Retrospective | Brm |
| Cutaneous | |
| Decreases | |
| History | |
| Icd | |
| Improves | |
| Increased | |
| Living | |
| Melanoma | |
| Metastasis | |
| Risk | |
| Survival | |
| Therapies |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | metastasis |
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | death |